IC-8 IOL submitted for premarket approval

February 23, 2021

1 min read

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AcuFocus has submitted a premarket approval application to the FDA for its IC-8 small aperture IOL.

The aspheric monofocal lens has an embedded filter with a central aperture. The lens is designed to minimize visual effects stemming from unfocused peripheral light, allowing central light rays to focus on the retina to deliver continuous extended depth of focus, according to a press release.

“The IC-8 IOL is a first-of-its-kind presbyopia-correcting lens that is designed to deliver seamless visual acuity from near to far without the ‘blurry zones’ found in traditional lens designs,” Magda Michna, PhD, chief global clinical, medical and regulatory affairs officer at AcuFocus, said in the release.

Safety and effectiveness of the IC-8 were evaluated in a prospective, multicenter, open-label, parallel-group, nonrandomized, examiner-masked, 1-year clinical study…

Want to know more click here go to source.

From Healio - February 24, 2021